Brief: China NT Pharma Group Updates On Potential Use Of "Ambroxol" For Coronavirus Treatment
29/01/2020 13:23
Jan 29 (Reuters) - China NT Pharma Group Company Ltd
1011.HK :
* WILL CLOSELY MONITOR DEVELOPMENT IN TREATMENTS FOR NEW
CORONAVIRUS INFECTIONS
* SCIENTISTS HAVE FOUND "AMBROXOL" HAS POTENTIAL TO BE USED
AS
TREATMENT FOR NEW CORONAVIRUS (2019-NCOV) INFECTIONS
* UPON CONFIRMATION, CO WILL COOPERATE WITH PRC GOVERNMENT
IN MASS
PRODUCTION OF ZHUO'AO, AN AMBROXOL
* UNIT SUZHOU FIRST PHARMACEUTICAL POSSESSES MEDICINE CALLED
ZHUO'AO, AN "AMBROXOL" (MUCOSOLVAN) MEDICINE
Source text for Eikon: urn:newsml:reuters.com:*:nHKS2fyQ5v
Further company coverage: 1011.HK
(Reuters.Briefs@thomsonreuters.com)
Recent news on China NT Pharma
See all newsBrief: China NT Pharma Receives Cietac Beijing Arbitration Award On July 20
Brief: China NT Pharma Establishes Formal Whistleblowing Policy
Brief: China NT Pharma Group Says Zhang Bozhi Resigns As CEO
Brief: China NT Pharma Group Says Expected Loss For Year Further Reduced By HK$15.4 Million As Compared With Prior Guidance
Brief: China Nt Pharma Expects Net Loss Attributable Of RMB25 MLN To RMB30 MLN In FY